BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE and CHRONIC OBSTRUCTIVE PULMONARY DISEASE

523 reports of this reaction

2.3% of all BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE reports

#12 most reported adverse reaction

Overview

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #12 most commonly reported adverse reaction for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, manufactured by AstraZeneca Pharmaceuticals LP. There are 523 FDA adverse event reports linking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 2.3% of all 23,211 adverse event reports for this drug.

Patients taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC OBSTRUCTIVE PULMONARY DISEASE523 of 23,211 reports

CHRONIC OBSTRUCTIVE PULMONARY DISEASE is a less commonly reported adverse event for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, but still significant enough to appear in the safety profile.

Other Side Effects of BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE

In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE:

Other Drugs Associated with CHRONIC OBSTRUCTIVE PULMONARY DISEASE

The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:

ACETYLCYSTEINEACLIDINIUM BROMIDEALBUTEROLARFORMOTEROL TARTRATEBUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATEFLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATEFLUTICASONE PROPIONATE AND SALMETEROLFLUTICASONE PROPIONATE AND SALMETEROL XINAFOATEGLYCOPYRROLATEIPRATROPIUM BROMIDEIPRATROPIUM BROMIDE AND ALBUTEROL SULFATEMANGANESE SULFATEROFLUMILASTSALMETEROL XINAFOATETHEOPHYLLINETHEOPHYLLINE ANHYDROUSTIOTROPIUM BROMIDETIOTROPIUM BROMIDE INHALATION SPRAYUMECLIDINIUMUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Frequently Asked Questions

Does BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE cause CHRONIC OBSTRUCTIVE PULMONARY DISEASE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 523 FDA reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC OBSTRUCTIVE PULMONARY DISEASE with BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE?

CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 2.3% of all adverse event reports for BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, making it a notable side effect.

What should I do if I experience CHRONIC OBSTRUCTIVE PULMONARY DISEASE while taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE?

If you experience chronic obstructive pulmonary disease while taking BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE Full ProfileAll Drugs Causing CHRONIC OBSTRUCTIVE PULMONARY DISEASEAstraZeneca Pharmaceuticals LP Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.